{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:40:20Z","timestamp":1768012820179,"version":"3.49.0"},"reference-count":50,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"DOI":"10.13039\/501100000351","name":"British Lung Foundation","doi-asserted-by":"publisher","award":["GSK\/BLF Chair of Respiratory Research"],"award-info":[{"award-number":["GSK\/BLF Chair of Respiratory Research"]}],"id":[{"id":"10.13039\/501100000351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2019,6,20]]},"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1183\/13993003.01213-2019","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T12:55:26Z","timestamp":1563454526000},"page":"1901213","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment to prevent exacerbations in bronchiectasis: macrolides as first line?"],"prefix":"10.1183","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8778-2823","authenticated-orcid":false,"given":"Irena F.","family":"Laska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"key":"2024101915221134000_54.1.1901213.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00051-2017"},{"key":"2024101915221134000_54.1.1901213.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02557-2017"},{"key":"2024101915221134000_54.1.1901213.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01532-2016"},{"key":"2024101915221134000_54.1.1901213.4","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-015-0167-9"},{"key":"2024101915221134000_54.1.1901213.5","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \u201cFrequent Exacerbator Phenotype\u201d in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101915221134000_54.1.1901213.6","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.04004"},{"key":"2024101915221134000_54.1.1901213.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01953-2017"},{"key":"2024101915221134000_54.1.1901213.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"},{"key":"2024101915221134000_54.1.1901213.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01090-2016"},{"key":"2024101915221134000_54.1.1901213.10","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212463"},{"key":"2024101915221134000_54.1.1901213.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02033-2017"},{"key":"2024101915221134000_54.1.1901213.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01987-2017"},{"key":"2024101915221134000_54.1.1901213.13","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2016.10.055","article-title":"Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry","volume":"151","author":"Aksamit","year":"2017","journal-title":"Chest"},{"key":"2024101915221134000_54.1.1901213.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02074-2018"},{"key":"2024101915221134000_54.1.1901213.15","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.chest.2017.04.167","article-title":"Pharmacotherapy for non-cystic fibrosis bronchiectasis: results from an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry","volume":"152","author":"Henkle","year":"2017","journal-title":"Chest"},{"key":"2024101915221134000_54.1.1901213.16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00689-2017"},{"key":"2024101915221134000_54.1.1901213.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00328-2018"},{"key":"2024101915221134000_54.1.1901213.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01582-2017"},{"key":"2024101915221134000_54.1.1901213.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01250-2017"},{"key":"2024101915221134000_54.1.1901213.20","first-page":"CD000996","article-title":"Inhaled corticosteroids for bronchiectasis","volume":"5","author":"Kapur","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101915221134000_54.1.1901213.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01896-2018"},{"key":"2024101915221134000_54.1.1901213.22","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(18)31554-X","article-title":"Bronchiectasis in children: diagnosis and treatment","volume":"392","author":"Chang","year":"2018","journal-title":"Lancet"},{"key":"2024101915221134000_54.1.1901213.23","first-page":"CD012406","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101915221134000_54.1.1901213.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2290"},{"key":"2024101915221134000_54.1.1901213.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60953-2"},{"key":"2024101915221134000_54.1.1901213.26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long term macrolide antibiotics for the treatment of bronchiectasis in adults- individual patient data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024101915221134000_54.1.1901213.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02052-2017"},{"key":"2024101915221134000_54.1.1901213.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02053-2017"},{"key":"2024101915221134000_54.1.1901213.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02444-2017"},{"key":"2024101915221134000_54.1.1901213.30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024101915221134000_54.1.1901213.31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00451-2017"},{"key":"2024101915221134000_54.1.1901213.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00037-2017"},{"key":"2024101915221134000_54.1.1901213.33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01219-2018"},{"key":"2024101915221134000_54.1.1901213.34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01848-2017"},{"key":"2024101915221134000_54.1.1901213.35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S2213-2600(15)00145-9","article-title":"Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts","volume":"3","author":"Brusselle","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024101915221134000_54.1.1901213.36","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02201-2016"},{"key":"2024101915221134000_54.1.1901213.37","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01655-2017"},{"key":"2024101915221134000_54.1.1901213.38","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"key":"2024101915221134000_54.1.1901213.39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-2600(18)30053-5","article-title":"Bronchiectasis: new therapies and new perspectives","volume":"6","author":"Chalmers","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024101915221134000_54.1.1901213.40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JAA.S196200","article-title":"Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab","volume":"12","author":"Carpagnano","year":"2019","journal-title":"J Asthma Allergy"},{"key":"2024101915221134000_54.1.1901213.41","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01269-2018"},{"key":"2024101915221134000_54.1.1901213.42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1164\/rccm.201809-1651OC","article-title":"Airway bacterial load and inhaled antibiotic response in bronchiectasis","volume":"200","author":"Sibila","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101915221134000_54.1.1901213.43","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02232-2017"},{"key":"2024101915221134000_54.1.1901213.44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01926-2017"},{"key":"2024101915221134000_54.1.1901213.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104623"},{"key":"2024101915221134000_54.1.1901213.46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170622"},{"key":"2024101915221134000_54.1.1901213.47","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(14)70213-9","article-title":"The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial","volume":"2","author":"Rogers","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024101915221134000_54.1.1901213.48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00766-2018"},{"key":"2024101915221134000_54.1.1901213.49","doi-asserted-by":"crossref","unstructured":"Bradley J, Boyle R.\u00a0A 2x2 factorial randomised open label trial to determine the CLinical and cost-Effectiveness of hypertonic saline (HTS 6%) and carbocisteine for Airway cleaRance versus usual care over 52 weeks in bronchiectasis (CLEAR). https:\/\/doi.org\/10.1186\/ISRCTN89040295 Date last updated: March 22, 2019.","DOI":"10.1186\/ISRCTN89040295"},{"key":"2024101915221134000_54.1.1901213.50","unstructured":"van der Eerden MM, de Koning Gans MJM. Formoterol\u2013beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial (FORZA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03846570 Date last updated: February 22, 2019."}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01213-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:41:20Z","timestamp":1740382880000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01213-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,7,18]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1183\/13993003.01213-2019"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01213-2019","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}